| Bioactivity | ML-T7 is a potent Tim-3 inhibitor. ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T cells but also increases the effector function of T cell. ML-T7 promotes NK cells’ killing activity against tumor cells and DC antigen-presenting capacity. ML-T7 directly exerts antitumor efficacy in preclinical tumor models either alone or in combination with Nivolumab (HY-P9903A). ML-T7 can be used for tumor immunotherapy research[1]. |
| Invitro | ML-T7(10 μM, 0-6 days) 通过Tim-3增强TCR/STAT5信号通路，促进CD8+细胞抗肿瘤活性[1]。ML-T7(10 μM, 24 h) 可通过Tim-3和Tim-4促进DC的成熟和功能,增强DC抗原呈递能力[1]。ML-T7(10 μM, 24 h) 增强CTL激活和细胞因子产生，减少CTLs的凋亡[1]。ML-T7(10 μM, 48 h) 可显著增强人NK 细胞系NK92细胞中IFN-γ、TNF-α、CD107a 和granzyme B的产生[1]。 0 --> ML-T7 相关抗体: Western Blot Analysis[1] Cell Line: |
| In Vivo | ML-T7 (10-50 mg/kg; 腹腔注射; every 2 days, 10 times) 抑制肿瘤生长并延长小鼠的生存期，对小鼠体重无不良影响[1]。ML-T7 (20 mg/kg; 腹腔注射; every 2 days, 10 times)和 Nivolumab (HY-P9903A)联合治疗可提升 Nivolumab (HY-P9903A)抗体的抗肿瘤效果，同时可有效提高HCC小鼠存活率[1]。ML-T7 (50 mg/kg, 腹腔注射; every 2 days for 3 weeks)在小鼠中表现出良好的安全性[1]。 Animal Model: |
| Name | ML-T7 |
| CAS | 459789-75-4 |
| Formula | C27H17Cl2NO5 |
| Molar Mass | 506.33 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ma S, et al. Identification of a small-molecule Tim-3 inhibitor to potentiate T cell-mediated antitumor immunotherapy in preclinical mouse models. Sci Transl Med. 2023 Nov 15;15(722):eadg6752. |